PointClickCare vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud-based EHR and care coordination platform for long-term and post-acute care organizations. Mississauga, Canada. Raised $172M+, unicorn. Serves 27,000+ care facilities across North America.
About
PointClickCare is North America's leading cloud-based software platform for the long-term and post-acute care (LTPAC) market, headquartered in Mississauga, Ontario, Canada. Founded in 1999, the company has raised over $172 million and achieved unicorn valuation status. PointClickCare serves over 27,000 care facilities including skilled nursing facilities, senior living communities, assisted living centers, and home health agencies across the United States and Canada. The platform provides electronic health records (EHR), billing, care coordination, and business intelligence capabilities.\n\nPointClickCare's platform is built around the complex clinical and regulatory workflows unique to post-acute care, which differ substantially from acute hospital EHR requirements. The system manages MDS assessments, care planning, medication administration records, therapy documentation, and the complex billing requirements for Medicare, Medicaid, and managed care payers. Its network effect is significant — because PointClickCare connects so many facilities, care transitions between hospitals and post-acute settings can be managed with streamlined data exchange.\n\nThe company has expanded through strategic acquisitions including Collective Medical, which added care transition and high-risk patient identification capabilities powered by a large hospital and payer data network. PointClickCare's Marketplace ecosystem allows third-party technology vendors to integrate with the platform, creating an app store model that extends its functionality without requiring PointClickCare to build every adjacent capability. As value-based care models push accountable care organizations to manage patient outcomes across the full episode of care, PointClickCare's position at the post-acute node of the care continuum becomes increasingly strategically important.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.